Debiopharm Group

BC Platforms specializes in genomic data management solutions aimed at tackling significant healthcare challenges. The company offers a robust data management platform that facilitates the integration, secure analysis, and interpretation of molecular and clinical data. By combining genomics with IT, BC Platforms empowers health organizations to make informed decisions in drug development and delivery. Their systematic and standardized approach allows for efficient handling of complex health data, ultimately supporting improved outcomes in healthcare.

Little Green House operates a chain of educational centers dedicated to enhancing children's cognitive abilities while prioritizing their emotional well-being and social skills. The organization aims to create an inclusive environment where children can express themselves freely and pursue their individual growth. Its centers offer diverse developmental activities, including play areas, site visits, and opportunities for learning musical instruments, all designed to foster the holistic development of children. Through these initiatives, Little Green House seeks to support the overall growth and development of young learners in a nurturing atmosphere.

Kaiku Health Oy develops and delivers user-centered software solutions for patients, doctors, and nurses to communicate online. It develops a communication and follow-up solution for cancer patients to communicate with medical staff in Swedish, English, German, and Finnish languages. The company serves clinics and university hospitals in Finland, Sweden, and Switzerland. Kaiku Health Oy was formerly known as Netmedi Oy and changed its name to Kaiku Health Oy in September 2017. The company was founded in 2012 and is based in Helsinki, Finland. As of May 15, 2020, Kaiku Health Oy operates as a subsidiary of Elekta AB (publ).

BC Platforms specializes in genomic data management solutions aimed at tackling significant healthcare challenges. The company offers a robust data management platform that facilitates the integration, secure analysis, and interpretation of molecular and clinical data. By combining genomics with IT, BC Platforms empowers health organizations to make informed decisions in drug development and delivery. Their systematic and standardized approach allows for efficient handling of complex health data, ultimately supporting improved outcomes in healthcare.

Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and innovative learning solutions, including massive open online courses (MOOCs). The company offers a learning experience platform that features a diverse catalog of training courses characterized by short, accessible sessions. This platform is designed to enhance digital learning for employees by providing customized content tailored to individual needs, making it easy for users to engage with the material at any time and across various mediums.

Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and innovative learning solutions, including massive open online courses (MOOCs). The company offers a learning experience platform that features a diverse catalog of training courses characterized by short, accessible sessions. This platform is designed to enhance digital learning for employees by providing customized content tailored to individual needs, making it easy for users to engage with the material at any time and across various mediums.

BPA Solutions SA specializes in providing innovative business applications that enhance Microsoft SharePoint and Office 365. Founded in 2001 and headquartered in Yverdon-les-Bains, Switzerland, the company develops a range of solutions including BPA CRM for customer relationship management, BPA Quality for quality management, and BPA Risk for tracking business activities in complex environments. Additional offerings include BPA Project for project management, BPA Recruiting for candidate management, and Self-Service tools for process sharing. BPA Solutions also features a Solutions Suite to monitor critical business processes and mobile solutions, along with professional services such as training, consulting, and support. The company delivers its software on-premise, through private or Microsoft clouds, and in hybrid environments, serving clients globally.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

Skioo is a developer of a ski-lift ticketing platform designed to streamline the booking of ski adventures. The company provides the Skioo Pass, which grants skiers instant access to a wide network of ski partner resorts in Switzerland and beyond. By synchronizing its platform with the systems of ski resorts and lift operators, Skioo enables users to conveniently purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community among skiing enthusiasts and offers valuable information and features to enhance the skiing experience. Founded in 2019 as part of the Skitude group, Skioo is supported by key technology partners, including Skidata AG and Team Axess AG.

KeyLemon S.A., founded in 2008 by Gilles Florey and Yann Rodriguez in Martigny, Switzerland, specializes in biometric authentication technology, particularly through face recognition. The company aims to provide a seamless and secure user experience by allowing devices to recognize their owners naturally, eliminating the need for passwords. KeyLemon has developed innovative solutions, including its flagship product, Oasis, which enables mobile authentication by simply taking a selfie. This technology is designed for various applications, enhancing secure access to high-value services such as banking and payment across multiple devices and systems. Over the years, KeyLemon has established itself as a leader in biometric solutions, serving a diverse clientele globally while remaining committed to continuous improvement in user recognition and security. As of 2018, KeyLemon operates as a subsidiary of ams AG.

Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.

Urturn is the new social platform for self-expression. Both on the Desktop and as an iPhone app, users are able to spontaneously capture moments of inspiration on-the-fly! The ever-growing library of Expression can be instantly personalised in all kinds of ways and the unique 'Your Turn' button lets users take inspiration from or join in with online movements in rich and interactive way. Spontaneous, engaging and fun, Urturn is the next natural step for social media. It's Urturn...

Compliant Concept is a spinoff of the Empa and the ETH Zurich. They develop intelligent bed systems for the treatment and prevention of pressure ulcers. compliant concept is a spin-off of ETH Zurich and Empa, with its roots in Empa's Laboratory for Mechanics for Modeling and Simulation. Their goal is to make the care of hospital patients and nursing home residents safer, more efficient and more comfortable.

Spinomix is a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector. Based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company is building the new gold standard for the processing of biochemical substances. Its products capture and extract samples at a quality and efficiency far superior to current practice, thus enabling more efficient diagnostics. The company’s main focus is on applications which are critical for treatment decisions in a variety of human diseases. Other applications target markets such as animal health and food safety. Spinomix’ products MagPhase™ and FibroTrap™ improve the accuracy and time taken to obtain meaningful results from samples that are highly heterogeneous and notoriously difficult to analyse (e.g. blood, urine, swabs and food matrices). Today many aspects of sample processing are still labour and time intensive. Therefore, there is a significant opportunity for Spinomix’s technologies to streamline the process. They are targeting double-digit growth markets such as nucleic acids extraction, believed to be worth $2 billion; cell separation growing to over $2.5 billion; food safety at over $2 billion; and molecular diagnostics for infectious diseases estimated at $2.7 billion. Their current approach is to concentrate on product innovation and market validation. They have collaboration agreements in place and are conducting validation programs of their products with key market players in research and industry. Their goal is to develop these collaborations into strategic commercial partnerships to license their products.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

Skioo is a developer of a ski-lift ticketing platform designed to streamline the booking of ski adventures. The company provides the Skioo Pass, which grants skiers instant access to a wide network of ski partner resorts in Switzerland and beyond. By synchronizing its platform with the systems of ski resorts and lift operators, Skioo enables users to conveniently purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community among skiing enthusiasts and offers valuable information and features to enhance the skiing experience. Founded in 2019 as part of the Skitude group, Skioo is supported by key technology partners, including Skidata AG and Team Axess AG.

Searchbox is a software company specializing in search technologies, with strong areas of expertise in cognitive sciences, data mining and computer sciences. Through its innovative technologies, Searchbox fundamentally changes the way people interact and consume information. Through highly customizable cloud based search solutions and plugins for Solr, these technologies are readily available for usage with a minimal amount of tinkering.

Tweasy helps businesses stay close to their customers and grow strong and profitable relationships. The Tweasy application brings together all the news, promotions, surveys and information generated by businesses, clubs and associations to help them communicate.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.